Clinical Trial

A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-11.
Trial Details
NCT Number NCT07652073
Lead Sponsor Danatlas Pharmaceuticals Co., Ltd
Conditions Advanced or Metastatic Ovarian Cancer
Enrollment 30 participants
Start Date 2026-06-15
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25